Firm targets control investments in essential service and manufacturing businesses with $2–$30 million in revenue and $1–$3 million in EBITDA.…
Firm targets control investments in essential service and manufacturing businesses with $2–$30 million in revenue and $1–$3 million in EBITDA.…
—Top 4% of Global Applicants Selected to Compete for $800K in Non-Dilutive Funding and Unmatched Industry Access— —Up to 13…
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland -…
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE,…
Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in…
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,…
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July…
In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL StudyPITTSBURGH, July…
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses…